DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

TreatmentTrends: Type 2 Diabetes (US) 2013

TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. They evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.
This BioTrends report focuses on the management of type 2 diabetes (T2D) and is authored by the Decision Resources metabolic disease team who has extensive experience in type 2 diabetes market research and analysis.

Questions Answered in This Report:

  • Understand the T2D patient population
    How many prediabetics and T2D patients are physicians treating and how does it differ between physician type?
    What is the prevalence of comorbidities (e.g. obesity, hypertension, dyslipidemia) within the T2D population?
    How many patients are referred to surveyed endocrinologists, at what point is the referral (e.g., lab values at referral), and what is the PCP’s relationship with the patient post-referral?

  • Understand the diagnosis and standard of care for patients with T2D and how therapy decisions differ based on disease presentation and specialty of physician treating
    What drug classes are most frequently prescribed in combination?
    What comorbidities (e.g. obesity, hypertension, dyslipidemia) influence prescribing decisions?
    How does the preference for certain drug classes or brands differ by physician specialty?

  • Understand the satisfaction with current treatment, potential for new pipeline products, and unmet need in the management of T2D
    How does each product in the study perform against competitors amongst ten different product attributes? How do the ratings differ between ENDOs and PCPs?
    What is the familiarity, interest, expected line of treatment, and percent of patients likely candidates for products in development for T2D?


Sample Methodology:

45 minute online quantitative survey with several open-ended questions for qualitative feedback completed by 102 endocrinologists, and 55 primary care physicians in the US

Screening Criteria:

- In practice between 2 and 30 years

- Over 75% of time spent on patient care

Endocrinologists have treated at least 100 patients with type 2 diabetes in the past year

PCPs have treated at least 50 patients with type 2 diabetes in the past year


- Report in PowerPoint format

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Access to analyst team for presentation or to address questions

Report Dates:

- Publish: October 17, 2013

- Field: September 10, 2013

Physician Research:

- 45 minute online quantitative survey with several open-ended questions for qualitative feedback completed by 102 US endocrinologists, and 55 US primary care physicians (PCPs)

Key Drugs Covered:

- SGLT-2 inhibitors (Invokana), GLP-1 analogues (Victoza, Byetta, Bydureon), PPAR-gamma agonists, DPP-IV inhibitors (Januvia, Janumet, Onglyza, Trajenta), Long-acting insulins (Lantus), Short-acting insulins, among other products including products in late-stage development.

Key Companies Mentioned:

- Lilly

- Boehringer Ingelheim

- Novo Nordisk

- AstraZeneca

- Bristol-Myers Squibb

- Janssen

- Merck

- AbbVie

- Sanofi

- Takeda


- Many more

Content Highlights:

- Updates: Key Market Events

- Current Therapies and Medical Practice

- Market Landscape Snapshot

- Product Perceptions

- Unmet Needs

- Emerging Therapies

- Key Competitors

- Detailing Reach and Frequency

- Brand Messages Recall

Related Reports and Products:

- TreatmentTrends: Diabetic Nephropathy (US)

- Pharmacor: Type 2 Diabetes

- Physician and Payer Forum (US): Type 2 Diabetes: First-in-Class SGLT-2 Inhibitors and Novel Insulins Appear on the Horizon: What Market Access Challenges Will These New Therapies Face?

- Physician and Payer Forum (US): E-Prescribing and Electronic Health Records: Impact of Technology on Prescribing for Hypertension and Diabetes

- Treatment Algorithms: Type 2 Diabetes